← All indications
Cystadenocarcinoma
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Subtype terms (3)
More specific conditions that are subtypes of Cystadenocarcinoma in the MeSH hierarchy.
- Cystadenocarcinoma, Mucinous
2 drugs approved
- Cystadenocarcinoma, Papillary
- Cystadenocarcinoma, Serous
3 drugs (2 approved, 1 experimental)
Organizations
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (22)
- Amgen
- Genentech
- Sanofi
- University of Pennsylvania
- University of Washington
- Mercy Medical Center
- Ohio State University
- University of Southern California
- University of Toronto
- Wake Forest University
- Mayo Clinic
- University of Chicago
- Icahn School of Medicine at Mount Sinai
- University of Texas at Houston
- State University of New York, Buffalo
- University of New South Wales
- Gateway for Cancer Research
- Yeshiva University
- Klus Pharma Inc.
- Chinese Academy of Medical Sciences
- Mucpharm Pty Ltd
- ThermaSolutions Inc.
Organization Involved with Phase 1 Indications (14)
- Millennium Pharmaceuticals
- Case Western Reserve University
- Harvard University
- Temple University
- Johns Hopkins University
- University of Kentucky
- University of Rochester
- Virginia Commonwealth University
- Stony Brook University
- University of California, Davis
- University of California, San Diego
- Vanderbilt University
- University of Wisconsin
- University of Western Ontario
Organization Involved with Other Experimental Indications (1)